Preclinical development of Ramizol, an antibiotic belonging to a new class, for the treatment of Clostridium difficile colitis

Antibiotic-resistant bacteria is a major threat to human health and is predicted to become the leading cause of death from disease by 2050. Despite the recent resurgence of research and development in the area, few antibiotics have reached the market, with most of the recently approved antibiotics c...

Descripción completa

Detalles Bibliográficos
Autores principales: Rao, Shasha, Prestidge, Clive A, Miesel, Lynn, Sweeney, Deb, Shinabarger, Dean L, Boulos, Ramiz A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399159/
https://www.ncbi.nlm.nih.gov/pubmed/27189122
http://dx.doi.org/10.1038/ja.2016.45

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399159/
https://www.ncbi.nlm.nih.gov/pubmed/27189122
http://dx.doi.org/10.1038/ja.2016.45

Ejemplares similares